GSK241213C33000
- 0.87
- -0.63-42.00%
GlaxoSmithKline Newsroom
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More
Anaptys Scraps Development of ANB032, Stock Plunges 33%
TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $45
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
India Drug Delivery Devices Market 2024, With Profiles of Pfizer, Novartis, GlaxoSmithKline, India Medtronic, Cardinal Health, B. Braun Medical, Sun Pharmaceutical, 3M, Cipla & Bayer Zydus Pharma
GSK, Relation Therapeutics Partner to Advance Osteoarthritis, Fibrotic Disease Treatments
Glaxosmithkline (GSK.US) drugs reduce the risk of death by 42% in multiple myeloma studies.
Glaxosmithkline (GSK.US) reported that a study shows its drug belantamab mafodotin can reduce the risk of death for patients with multiple myeloma at first relapse or post-relapse by 42%.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Sector Update: Health Care
GSK's DREAMM-7 Trial Shows Sustained Overall Survival Benefit For Belantamab Mafodotin Combination Versus Daratumumab Combination; Benefit Seen Early And Maintained Through Follow-up, Reducing The Risk Of Death By 42% In Multiple Myeloma At Or After...
GSK: Data Compares With Competitor Drug Johnson & Johnson's Darzalex
GSK: Data Supports Potential for Blenrep Combinations to Become Standard of Care
GSK: Data Is For Patients With Multiple Myeloma at or After First Relapse
GSK: Blenrep Is Treatment for Relapsed/Refractory Multiple Myeloma
GSK: Data Projects Patients on Blenrep Combination To Survive Nearly Three Years Longer Compared to Standard of Care
GSK: Blenrep Combination Late-Stage Trial Reduced Risk of Death by 42% in Patients With Multiple Myeloma at or After First Relapse